Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
Citations
1,988 citations
712 citations
Cites methods from "Selumetinib in women with recurrent..."
...Mutational analyses were performed in tumors from 34 patients, and KRAS and BRAF mutations were found in 41% and 6%, respectively, although mutations did not correlate with response or longer progression-free survival.(100) These examples argue against a preponderant role of the MAPK/ERK pathway as a targeting oncogenic driver in these tumors despite the presence of mutations....
[...]
702 citations
663 citations
624 citations
Additional excerpts
...Despite promising results with selumetinib, an MEK1/2 inhibitor [237], no correlation was found between BRAF or KRAS mutation status and therapeutic response in patients with recurrent low-grade serous ovarian cancer....
[...]
References
14,926 citations
1,134 citations
1,008 citations
1,005 citations
842 citations